MARKET

BFRA

BFRA

Biofrontera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.52
+0.01
+0.15%
Closed 16:00 06/01 EDT
OPEN
6.52
PREV CLOSE
6.51
HIGH
6.52
LOW
6.52
VOLUME
14
TURNOVER
--
52 WEEK HIGH
18.26
52 WEEK LOW
5.41
MARKET CAP
146.21M
P/E (TTM)
-10.7893
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BFRA stock price target is 15.50 with a high estimate of 20.00 and a low estimate of 11.00.

EPS

BFRA News

More
Results of the 2020 Annual General Meeting of Biofrontera AG
GlobeNewswire · 4d ago
Biofrontera AG to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 2:00 PM Eastern ...
ACCESSWIRE · 05/20 16:00
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/20 15:46
Biofrontera reports Q1 2020 financial results
GlobeNewswire · 05/19 15:15
Biofrontera Dismisses Unfair Competition Case vs DUSA Pharmaceuticals in California State Court
Biofrontera AG (NASDAQ: BFRA) today comments on certain litigation in California state court between the Company and DUSA Pharmaceuticals, Inc. ("DUSA").
Benzinga · 05/13 09:49
Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
GlobeNewswire · 05/13 09:00
Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
GlobeNewswire · 05/12 16:00
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 8 stocks hit new 52-week lows.
Benzinga · 05/07 15:39

Industry

Pharmaceuticals
-1.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About BFRA

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
More

Webull offers kinds of Biofrontera AG (ADR) stock information, including NASDAQ:BFRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRA stock news, and many more online research tools to help you make informed decisions.